We rank companies based on fund manager, research analyst and news sentiment
ARGX

argenx
ARGX

$360.23
0.51%
 

About: Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was approved in the U.S. in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.

Employees: 1,148

0
Funds holding %
of 6,474 funds
0
Analysts bullish %
of 31 analysts
0
News positive %
of 6 articles

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

56% more call options, than puts

Call options by funds: $265M | Put options by funds: $170M

45% more repeat investments, than reductions

Existing positions increased: 145 | Existing positions reduced: 100

2% more first-time investments, than exits

New positions opened: 62 | Existing positions closed: 61

0% more funds holding

Funds holding: 333 [Q3] → 334 (+1) [Q4]

0.14% more ownership

Funds ownership: 55.26% [Q3] → 55.4% (+0.14%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 25 [Q3] → 25 (+0) [Q4]

22% less capital invested

Capital invested by funds: $15.9B [Q3] → $12.5B (-$3.45B) [Q4]

Research analyst outlook

31 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$346
4%
downside
Avg. target
$502
39%
upside
High target
$641
78%
upside

31 analyst ratings

28 positive
90%
neutral
10%
negative
0%
Wedbush
David Nierengarten
45%upside
$521
Outperform
Reiterated
18 Apr 2024
HC Wainwright & Co.
Douglas Tsao
25%upside
$451
Buy
Reiterated
18 Apr 2024
HC Wainwright & Co.
Douglas Tsao
25%upside
$451
Buy
Maintained
27 Mar 2024
Scotiabank
George Farmer
13%upside
$408
Sector Perform
Maintained
26 Mar 2024
JMP Securities
Jason Butler
31%upside
$471
Market Outperform
Reiterated
22 Mar 2024

Financial journalist opinion

Based on 6 articles about ARGX published over the past 30 days